RT @uptoTate: UPA tx in prior TNFi tx PsA pts demonstrated consistent efficacy compared to the overall population in SEL

Tweet Author

Tweet Content

UPA tx in prior TNFi tx PsA pts demonstrated consistent efficacy compared to the overall population in SELECT-PsA 2, regardless of number of prior anti-TNF therapies. Abs 2146 #ACR22 @RheumNow https://t.co/xnN4nvZ934 https://t.co/3S6ZzPvqVe

Links

Efficacy of Upadacitinib in Patients with Psoriatic Arthritis and Prior Exposur… http://ow.ly/1TXr50LAlsM

RT @RHEUMarampa: How to adjust for GC correction when dose >/= 7.5mg/d using FRAX? Calculate FRAX then ð¦´For MOF r

Tweet Author

RHEUMarampa

Tweet Content

How to adjust for GC correction when dose >/= 7.5mg/d using FRAX? Calculate FRAX then 🦴For MOF risk multiply by 1.15 🦴HF risk multiply by 1.2 = adjusted risk (%) (Adjustment of FRAX accdg to GC dose from Kanis et al., OI 2011) #ACR22 @RheumNow @Rheumarhyme @PhRheumaJr https://t.co/qap1fFhF0h

14 November 2022

ACR22: Polymyalgia Rheumatica in the Spotlight

One of the enduring legacies of ACR 2022 for me will be the emphasis on polymyalgia rheumatica (PMR). Despite being highly inflammatory and relatively common, a remarkable paucity of trials have been run in this space. Read on for a quick PMR-roundup from the meeting!

RT @Janetbirdope: What happens to #Sjogrens tests over time? Well nothing- serology and tests are stable over time for

Tweet Author

Janetbirdope

Tweet Content

What happens to #Sjogrens tests over time? Well nothing- serology and tests are stable over time for NIH in >2800 Pts from 1984-2020 in well characterized Pts. Abst#2025 #ACR22 @RheumNow I was surprised as I thought there would be worsening but if prevalent Pts already fibrotic?

RT @RichardPAConway: Wheeler et al. MUC5B assoc risk RA-ILD, OR 2.25. No significant additive interaction with race, smo

Tweet Author

RichardPAConway

Tweet Content

Wheeler et al. MUC5B assoc risk RA-ILD, OR 2.25. No significant additive interaction with race, smoking, disease activity @RheumNow #ACR22 Abstr#2250 https://t.co/Hw2oBawKsd https://t.co/DqCQIPpEyg

Links

Genetic and Environmental Risk Factors in Rheumatoid Arthritis-Associated Inter… https://acrabstracts.org/abstract/genetic-and-environmental-risk-factors-in-rhe…

RT @AkhilSoodMD: Abstr #2195 COVID PrEP in Rheum pts who did not seroconvert after 3rd dose - anti-SARS-CoV2 IgG levels

Tweet Author

AkhilSoodMD

Tweet Content

Abstr #2195 COVID PrEP in Rheum pts who did not seroconvert after 3rd dose - anti-SARS-CoV2 IgG levels ↑ after day 1 - Saliva IgG also ↑ up to day 14 - one reported COVID+ w mild symptoms @RheumNow #ACR22 https://t.co/um2JFNMhpj

RT @RichardPAConway: Zuo @RayZuoMD @jasonsknight et al. High levels of anti-NET antibodies in 45% of aPL-positive patien

Tweet Author

RichardPAConway

Tweet Content

Zuo @RayZuoMD @jasonsknight et al. High levels of anti-NET antibodies in 45% of aPL-positive patients May activate the complement cascade and contribute to brain white matter changes. @RheumNow #ACR22 Abstr#2269 https://t.co/JrjNvQRDim https://t.co/c4yXHLOmBJ

Links

Anti-NET Antibodies in Antiphospholipid Antibody-positive Patients: Results fro… https://acrabstracts.org/abstract/anti-net-antibodies-in-antiphospholipid-antib…

RT @Janetbirdope: ILD in #scleroderma. #Scleroderma lung study III - NO DIFF between MMF + Pirfenidone vs MMF alone. Pla

Tweet Author

Janetbirdope

Tweet Content

ILD in #scleroderma. #Scleroderma lung study III - NO DIFF between MMF + Pirfenidone vs MMF alone. Planned for 150 Pts but only 51 enrolled but p=0.9. A trial recruited during #COVID so difficult to enroll Abst#530 @RheumNow #ACR22 https://t.co/CBYEJ2YCVM

RT @DrCassySims: How does #COVID19 impact pregnant women with rheumatic disease? Does vaccination status make a differen

Tweet Author

DrCassySims

Tweet Content

How does #COVID19 impact pregnant women with rheumatic disease? Does vaccination status make a difference? @RheumNow #ACR22 https://t.co/2oJ1RAeciN https://t.co/c9s6QRSOR4

Links

Impact of COVID 19 on Pregnancies in Women with RMD - YouTube https://youtu.be/EoKO_VgrU-A

RT @RichardPAConway: Baker et al. Optum database study. Tofa assoc reduced incident RA-ILD. aHR 0.33 (vs ADA) @RheumNow

Tweet Author

RichardPAConway

Tweet Content

Baker et al. Optum database study. Tofa assoc reduced incident RA-ILD. aHR 0.33 (vs ADA) @RheumNow #ACR22 Abstr#2251 #ACRbest https://t.co/R5rQ3KcHnq https://t.co/8Nq0t4zqQK

Links

Reduction in Rheumatoid Arthritis-Associated Interstitial Lung Disease Risk in … https://acrabstracts.org/abstract/reduction-in-rheumatoid-arthritis-associated-…

Topics

RT @uptoTate: UPA tx in prior TNFi tx PsA pts demonstrated consistent efficacy compared to the overall population in SEL

RT @RHEUMarampa: How to adjust for GC correction when dose >/= 7.5mg/d using FRAX? Calculate FRAX then ð¦´For MOF r

RT @Janetbirdope: What happens to #Sjogrens tests over time? Well nothing- serology and tests are stable over time for

RT @RichardPAConway: Wheeler et al. MUC5B assoc risk RA-ILD, OR 2.25. No significant additive interaction with race, smo

RT @AkhilSoodMD: Abstr #2195 COVID PrEP in Rheum pts who did not seroconvert after 3rd dose - anti-SARS-CoV2 IgG levels

RT @RichardPAConway: Zuo @RayZuoMD @jasonsknight et al. High levels of anti-NET antibodies in 45% of aPL-positive patien

RT @Janetbirdope: ILD in #scleroderma. #Scleroderma lung study III - NO DIFF between MMF + Pirfenidone vs MMF alone. Pla

RT @DrCassySims: How does #COVID19 impact pregnant women with rheumatic disease? Does vaccination status make a differen

RT @RichardPAConway: Baker et al. Optum database study. Tofa assoc reduced incident RA-ILD. aHR 0.33 (vs ADA) @RheumNow

Do you get our email newsletter?

RT @uptoTate: UPA tx in prior TNFi tx PsA pts demonstrated consistent efficacy compared to the overall population in SEL

RT @RHEUMarampa: How to adjust for GC correction when dose &gt;/= 7.5mg/d using FRAX? Calculate FRAX then ð¦´For MOF r

RT @Janetbirdope: What happens to #Sjogrens tests over time? Well nothing- serology and tests are stable over time for

RT @RichardPAConway: Wheeler et al. MUC5B assoc risk RA-ILD, OR 2.25. No significant additive interaction with race, smo

RT @AkhilSoodMD: Abstr #2195 COVID PrEP in Rheum pts who did not seroconvert after 3rd dose - anti-SARS-CoV2 IgG levels

RT @RichardPAConway: Zuo @RayZuoMD @jasonsknight et al. High levels of anti-NET antibodies in 45% of aPL-positive patien

RT @Janetbirdope: ILD in #scleroderma. #Scleroderma lung study III - NO DIFF between MMF + Pirfenidone vs MMF alone. Pla

RT @DrCassySims: How does #COVID19 impact pregnant women with rheumatic disease? Does vaccination status make a differen

RT @RichardPAConway: Baker et al. Optum database study. Tofa assoc reduced incident RA-ILD. aHR 0.33 (vs ADA) @RheumNow

RT @RHEUMarampa: How to adjust for GC correction when dose >/= 7.5mg/d using FRAX? Calculate FRAX then ð¦´For MOF r